Navigation Links
Options increase for CML patients failed by existing drugs
Date:12/21/2012

HOUSTON The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia chromosome (Ph+ALL). It approved the drug ponatinib (Iclusig), which is effective in a significant number of patients with either disease.

Patients with both leukemias have enjoyed strong responses to imatinib (Gleevec) and second-generation drugs nilotinib (Tasigna) and dasatinib (Sprycel). All work by inhibiting proteins called tyrosine kinases on leukemia cells, in particular the aberrant BCR-ABL protein that causes these diseases.

However, 30-40 percent of CML patients resist imatinib. Nilotinib and dasatinib work for about 40-50 percent of those patients.

"Ponatinib's availability will drastically improve the outcome of most patients with CML and PH+ALL who are resistant or intolerant to prior tyrosine kinase inhibitor therapy," said Jorge Cortes, M.D., professor and deputy chair, in The University of Texas MD Anderson Cancer Center Department of Leukemia.

"Clinical responses to Iclusig have been observed in patients regardless of their mutation status or disease stage. It's a valuable new treatment option for leukemia patients," Cortes said.

New drugs fill gaps in treatment

Ponatinib is the third drug approved by the FDA for CML and Ph+ALL during the past four months, providing oncologists with a wealth of options. Cortes led all of the clinical trials for the three drugs. The other two are bosutinib (Bosulif) and omacetaxine (Synribo). Cortes and other Leukemia Department faculty also led many of the clinical trials for the three previously approved CML therapies.

"It's important to have as many therapies against cancer as we can, because rarely does one drug or combination succeed for all patients," Cortes said. "These new drugs cover different gaps in treatment, so they can serve our patients in different way
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-516-4855
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Version 2.0 of Award-Winning Proloquo2Go App for iPhone, iPad & iPod touch Speeds Up Communication, Adds New Voices and Customization Options
2. Mesothelioma Victims Center Now Urges US Navy Veterans Or Individuals With Mesothelioma To Call Them For The Names Of The Best Mesothelioma Attorneys & Treatment Options
3. Menu labeling requirements lead to healthier options at chain restaurants
4. Options Increasing for Coping With Kids Food Allergies
5. Existing drugs offer new treatment options for high-risk childhood leukemia subtype
6. Many options, good outcomes, for early-stage follicular lymphoma
7. Little evidence supports autism treatment options in adolescents
8. New options for ease and accuracy in extraction of rare cells or separating blood
9. Policy considerations pose options for leaders to reduce costly disparities in diabetes
10. Fast food menu options double; calorie counts remain high
11. Tamoxifen trial should prompt breast cancer patients to reconsider treatment options
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... UWDress.com, a leading online supplier of wedding dresses and women’s ... empire bridesmaid dresses to its product line. In addition ... these high quality items. All of them are now available ... , The company’s new items can definitely add beauty ... website. It is true that all its products are more ...
(Date:8/22/2014)... CA (PRWEB) August 22, 2014 Japantown ... offering a new teeth whitening technique. Air polishing is ... cleaning appointments. , Dark teeth can be caused by ... categories: external stains and internal stains. External stains include ... can be caused by certain medications, such as tetracycline, ...
(Date:8/22/2014)... Amy Norton HealthDay Reporter ... growing number of Americans on work disability chronically use ... Researchers found that between 2007 and 2011, about 44 ... were prescribed narcotic painkillers each year. And the percentage ... 2007 to 23 percent in 2011. Experts ...
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... that uses university-proven research to show people how they can ... lean muscle in only a matter of weeks has caught ... , “Ben Pakulski is one of the most well-known bodybuilders ... get the body he has today, that in itself is ...
Breaking Medicine News(10 mins):Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2Health News:Japantown Dental Introduces Air Polishing 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2
... to bring an end to the double–penalty system for health trusts ... a health trust falls into deficit, not only is it penalized ... money is cut off from its allocated funds from the ensuing ... health trusts find it virtually impossible to balance accounts and have ...
... Millions of Americans whose vision is slowly ebbing due to ... the lowly neural progenitor cell may be useful for restoring ... rats, neural progenitor cells derived from human fetal stem cells ... degenerative eye disease similar to the kinds of diseases that ...
... control high blood pressure and new drugs that target ... have designed two promising new cardiovascular treatment approaches, a ... to lower high blood pressure and a therapeutic hybrid ... ,In the process, they have overcome ...
... new study finds the popular anti-clotting drug clopidogrel (Plavix) when ... safe without any adverse bleeding event.// ,The ... 56th Annual Scientific Session on March 27 at 9 am ... aspirin, will not worsen bleeding after off-pump heart bypass surgery. ...
... multi-center study concludes that women with a recent diagnosis of ... opposite breast.// ,This study was conducted by ... ,The international research team found that MRI, or ... 30 of 969 women (3.1 percent) who had recently been ...
... considering vaccinating young girls against a virus that causes cervical ... Robert Koch-Institute in Germany has recommended the universal vaccination of ... ,The Italian Ministry of Health has announced that vaccination of ... as regional vaccination centers are prepared. ,Government ...
Cached Medicine News:Health News:Double-penalty System for Bankrupt Health Trusts Lifted 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 2Health News:Stem Cell Therapy Shows Promise for Rescuing Deteriorating Vision 3Health News:Hormone-based Heart Pill to Control High Blood Pressure 2Health News:Hormone-based Heart Pill to Control High Blood Pressure 3Health News:Plavix Safe During and After Heart Bypass 2Health News:MRI Screening of Other Breast Crucial for Patients Diagnosed With Cancer in One Breast 2
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Eisai Limited is pleased to ... the first-of-its-kind comic book available in Canada ... designed specifically to educate children and their parents about epilepsy, ... affecting more than 300,000 Canadians. Eisai is guided by ... , in which the patient is central – there was ...
(Date:8/21/2014)... 2014  Decision Resources Group finds that, for ... Brazil and Mexico ... prescribe long-acting beta-agonist (LABA)- and long-acting muscarinic antagonist ... current severe cost/coverage constraints. Therefore, new brands of ... launch in these countries—which will considerably expand the ...
(Date:8/21/2014)... , N.Y. and HAMBURG, Germany , ... announced it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ... Germany , to speed up management and storage ... Big Data and Analytics architecture based on IBM ... per second of data at peak performance and help ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... 15 Prometheus Laboratories Inc., a specialty pharmaceutical ... launch of three new cancer diagnostic products: ProOnc ... Dx. Each of these tests is based on ... has a long and successful history of providing ...
... Oct. 15 Aethlon Medical, Inc. (OTC Bulletin Board: ... treatment of Hepatitis-C (HCV) infected patients with the Aethlon ... & Scientific Exposition of the American Society of Nephrology ... studies and Director of Nephrology at the Fortis Hospital ...
Cached Medicine Technology:Prometheus Launches ProOnc Dx Cancer Diagnostics 2Prometheus Launches ProOnc Dx Cancer Diagnostics 3Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 2Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 3
... Thermo Scientific Finnpipette Dispenser cover all volumes ... very high consistency, precision and reproducibility, due ... The Finnpipette Dispenser range is the latest ... manual liquid handling products, offering users reliability ...
... compact, mobile femtosecond surgical laser, has been ... for a wide spectrum of applications in ... demand of refractive surgeons for an "all-Laser ... efficient LASIK work-flow. The solution by Ziemer ...
... EHEC is the first one-step 20 minutes rapid ... and 2 produced by Enterohemorrhagic Escherichia coli in ... overnight enrichment of fecal specimens and detects all ... The separate result for Toxin 1 and 2 ...
Inquire...
Medicine Products: